METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC

Objectives To investigate the inhibitory effects of STM2457, which is a novel METTL3 (m6A writer) inhibitor, both as a monotherapy and in combination with anlotinib, in the treatment of oral squamous cell carcinoma (OSCC) both in vitro and in vivo. Materials and Methods The efficacy of STM2457 or ST...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oral diseases 2024-10, Vol.30 (7), p.4243-4254
Hauptverfasser:	Liu, Lianlian, Zhao, Tingting, Zheng, Siyi, Tang, Dongxiao, Han, Hui, Yang, Chunlong, Zheng, Xin, Wang, Juan, Ma, Jieyi, Wei, Wei, Wang, Zhaoyu, He, Shuqi, He, Qianting
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals anlotinib Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis Apoptosis - drug effects Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Cell cycle Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects EGFR Epidermal growth factor receptors Epithelial-Mesenchymal Transition - drug effects ErbB Receptors - antagonists & inhibitors Humans Immunofluorescence Immunohistochemistry Indoles - pharmacology Indoles - therapeutic use Methyltransferases Mice Mice, Nude Molecular modelling Mouth Neoplasms - drug therapy Mouth Neoplasms - pathology Oral carcinoma Oral squamous cell carcinoma Quinolines - pharmacology Quinolines - therapeutic use STM2457 Tumors Western blotting Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!